Cardiol Therapeutics Management
Management criteria checks 2/4
Cardiol Therapeutics' CEO is David Elsley, appointed in Jan 2017, has a tenure of 7.83 years. total yearly compensation is CA$748.10K, comprised of 70.2% salary and 29.8% bonuses, including company stock and options. directly owns 1.51% of the company’s shares, worth €1.87M. The average tenure of the management team and the board of directors is 3.9 years and 2.8 years respectively.
Key information
David Elsley
Chief executive officer
CA$748.1k
Total compensation
| CEO salary percentage | 70.2% |
| CEO tenure | 7.8yrs |
| CEO ownership | 1.5% |
| Management average tenure | 3.9yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CA$36m |
| Jun 30 2024 | n/a | n/a | -CA$29m |
| Mar 31 2024 | n/a | n/a | -CA$30m |
| Dec 31 2023 | CA$748k | CA$525k | -CA$28m |
| Sep 30 2023 | n/a | n/a | -CA$28m |
| Jun 30 2023 | n/a | n/a | -CA$30m |
| Mar 31 2023 | n/a | n/a | -CA$29m |
| Dec 31 2022 | CA$654k | CA$525k | -CA$31m |
| Sep 30 2022 | n/a | n/a | -CA$30m |
| Jun 30 2022 | n/a | n/a | -CA$32m |
| Mar 31 2022 | n/a | n/a | -CA$32m |
| Dec 31 2021 | CA$1m | CA$455k | -CA$32m |
| Sep 30 2021 | n/a | n/a | -CA$35m |
| Jun 30 2021 | n/a | n/a | -CA$30m |
| Mar 31 2021 | n/a | n/a | -CA$27m |
| Dec 31 2020 | CA$517k | CA$450k | -CA$21m |
| Sep 30 2020 | n/a | n/a | -CA$14m |
| Jun 30 2020 | n/a | n/a | -CA$13m |
| Mar 31 2020 | n/a | n/a | -CA$13m |
| Dec 31 2019 | CA$450k | CA$450k | -CA$14m |
| Sep 30 2019 | n/a | n/a | -CA$20m |
| Jun 30 2019 | n/a | n/a | -CA$21m |
| Mar 31 2019 | n/a | n/a | -CA$19m |
| Dec 31 2018 | CA$713k | CA$363k | -CA$16m |
Compensation vs Market: David's total compensation ($USD535.08K) is about average for companies of similar size in the German market ($USD479.80K).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
CEO
David Elsley
7.8yrs
Tenure
CA$748,100
Compensation
Mr. David G. Elsley, MBA, has been the President, Chief Executive Officer and Director of Cardiol Therapeutics Inc since January 19, 2017. Mr. Elsley is a business leader with a proven track record of deve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.8yrs | CA$748.10k | 1.51% € 1.9m | |
| CFO, Corporate Secretary & Director | 6.3yrs | CA$294.80k | 0.14% € 170.9k | |
| Chief Operating Officer | 3.9yrs | CA$515.90k | 0.038% € 46.6k | |
| Chief Medical Officer & Head of Research & Development | 3.7yrs | CA$746.56k | 0.56% € 695.8k | |
| Investor Relations | no data | no data | no data | |
| Vice President of Corporate Development | less than a year | no data | no data |
3.9yrs
Average Tenure
Experienced Management: CT9's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.8yrs | CA$748.10k | 1.51% € 1.9m | |
| CFO, Corporate Secretary & Director | 2.5yrs | CA$294.80k | 0.14% € 170.9k | |
| Independent Director | 4.9yrs | CA$60.00k | 0.18% € 221.5k | |
| Independent Director | 2.7yrs | CA$76.92k | 0.13% € 155.4k | |
| Independent Director | 6.9yrs | CA$58.00k | 0.58% € 726.2k | |
| Independent Director | 3.2yrs | CA$71.52k | 1.07% € 1.3m | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Independent Director | 2.5yrs | CA$82.32k | 0.15% € 186.5k | |
| Independent Chairman | 6.3yrs | CA$112.68k | 0.28% € 342.7k | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data |
2.8yrs
Average Tenure
56yo
Average Age
Experienced Board: CT9's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.